CLOV Earnings

CLOV reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 472.50M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.05 by 0%. The stock experienced a -2.79% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CLOV's earnings announcement on 2026-02-26, the stock price moved by -2.79% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CLOV's stock price tends to shift by an average of -3.63% in the 10 days leading up to earnings and 2.79% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CLOV's annual revenue to reach 467.06M, while the EPS is projected at -0.10. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CLOV's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CLOV's stock price typically moves by -3.63% in the 10 days before its earnings and 2.79% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.10 and revenue of 467.06M.

The company demonstrated strong financial performance with a 41% increase in insurance revenue and full-year adjusted EBITDA profitability. Membership growth and controlled medical cost trends contributed to a 40% increase in total revenue. Despite a slight decline in gross profit margin, the profitability of new cohorts is expected to improve. The strategic focus on expanding the Clover Assistant and Counterpart Health, along with disciplined cost management, supports a positive outlook. However, management's lack of specific guidance for certain initiatives and lowered 2025 EBITDA guidance temper the overall sentiment.